Merrimack currently has four targeted therapeutic oncology candidates in clinical development and a fifth that Merrimack expects to enter clinical development by the end of 2011. Additionally, Merrimack has multiple product candidates in preclinical development and an active Network Biology driven discovery effort. Merrimack owns global commercialization rights to all of its product candidates other than rights in Taiwan to MM-398 and worldwide rights to MM-121, which Merrimack has partnered with Sanofi and have a right to co-promote in the United States. For more information on a specific program, please click on the product candidate number on the left of the page.
